OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

globenewswire

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors – NEWSnet – News… as it used to be

More Press Releases

October 14, 2026

Leonardo DRS Expands Federal Access to Mission-Critical Technologies Through NASA SEWP VI

October 14, 2026

Datadog Announces Date of Third Quarter Fiscal Year 2026 Earnings Call

October 14, 2026

ServisFirst Bancshares, Inc. Announces Inaugural Stock Repurchase Program

October 14, 2026

OBI Pharma Announces Phase 1/2 Study Initiation for OBI-902, a TROP2 Targeted Antibody-Drug Conjugate Therapy (ADC) in Advanced Solid Tumors

Leonardo DRS Expands Federal Access to Mission-Critical Technologies Through NASA SEWP VI

Datadog Announces Date of Third Quarter Fiscal Year 2026 Earnings Call

ServisFirst Bancshares, Inc. Announces Inaugural Stock Repurchase Program

Silvaco Announces Date of Third Quarter 2026 Financial Results Conference Call